Last 12 months
Inside the activity.
15 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 4 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 3 | 0 |
| Sep 2026 | 4 | 0 |
| Oct 2026 | 3 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,009 | $68.69 | $69,305.59 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.44 to $68.995, inclusive. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 2,991 | $67.98 | $203,342.24 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,009 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $67.385 to $68.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 01:32 UTC |
Zago Wagner M.Chief Scientific Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $12.15 | $48,600.00 |
DisclosureSEC source: 0001140361-23-033192 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 5, 2023 21:33 UTC |
Karp Carol D.Chief Regulatory Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-033193 · form4.xml · derivative · entry 4 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 5,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 05, 2023 Filed Jul 5, 2023 21:33 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,034 | $68.69 | $71,027.42 |
DisclosureSEC source: 0001140361-23-033193 · form4.xml · nonDerivative · entry 3 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.44 to $68.99, inclusive. Read SEC document |
| July 05, 2023 Filed Jul 5, 2023 21:33 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 3,966 | $67.98 | $269,608.68 |
DisclosureSEC source: 0001140361-23-033193 · form4.xml · nonDerivative · entry 2 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,034 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $67.385 to $68.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| July 05, 2023 Filed Jul 5, 2023 21:33 UTC |
Karp Carol D.Chief Regulatory Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $12.15 | $60,750.00 |
DisclosureSEC source: 0001140361-23-033193 · form4.xml · nonDerivative · entry 1 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 22:16 UTC |
Selkoe Dennis J.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001140361-23-032854 · form4.xml · derivative · entry 4 Selkoe Dennis J. · CIK 0001582306 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 5,000 shares Expires 2030-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares subject to the option have fully vested. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 22:16 UTC |
Selkoe Dennis J.Director
|
SaleOrdinary Shares, par value $0.01 per share | 5,000 | $67.43 | $337,150.00 |
DisclosureSEC source: 0001140361-23-032854 · form4.xml · nonDerivative · entry 2 Selkoe Dennis J. · CIK 0001582306 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,845 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 22:16 UTC |
Selkoe Dennis J.Director
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $11.33 | $56,650.00 |
DisclosureSEC source: 0001140361-23-032854 · form4.xml · nonDerivative · entry 1 Selkoe Dennis J. · CIK 0001582306 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:45 UTC |
Malecek Michael JChief Legal Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0001140361-23-032003 · form4.xml · derivative · entry 5 Malecek Michael J · CIK 0001779336 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 5,000 shares Expires 2029-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on July 1, 2020, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:45 UTC |
Malecek Michael JChief Legal Officer
|
SaleOrdinary Shares, par value $0.01 per share | 710 | $70.84 | $50,295.41 |
DisclosureSEC source: 0001140361-23-032003 · form4.xml · nonDerivative · entry 4 Malecek Michael J · CIK 0001779336 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2022. F4 · price: The transaction was executed in multiple trades in prices ranging from $70.48 to $71.07, inclusive. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:45 UTC |
Malecek Michael JChief Legal Officer
|
SaleOrdinary Shares, par value $0.01 per share | 3,050 | $69.89 | $213,177.92 |
DisclosureSEC source: 0001140361-23-032003 · form4.xml · nonDerivative · entry 3 Malecek Michael J · CIK 0001779336 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 710 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $69.47 to $70.345, inclusive. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:45 UTC |
Malecek Michael JChief Legal Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,240 | $69.07 | $85,644.32 |
DisclosureSEC source: 0001140361-23-032003 · form4.xml · nonDerivative · entry 2 Malecek Michael J · CIK 0001779336 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,760 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 20, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $68.425 to $69.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:45 UTC |
Malecek Michael JChief Legal Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $10.27 | $51,350.00 |
DisclosureSEC source: 0001140361-23-032003 · form4.xml · nonDerivative · entry 1 Malecek Michael J · CIK 0001779336 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC |
Walker Karin LChief Accounting Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · derivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC |
Walker Karin LChief Accounting Officer
|
SaleOrdinary Shares, par value $0.01 per share | 529 | $69.99 | $37,026.88 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F4 · price: The transaction was executed in multiple trades in prices ranging from $69.91 to $70.20, inclusive. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC |
Walker Karin LChief Accounting Officer
|
SaleOrdinary Shares, par value $0.01 per share | 2,471 | $69.49 | $171,698.92 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.90 to $69.85, inclusive. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC |
Walker Karin LChief Accounting Officer
|
SaleOrdinary Shares, par value $0.01 per share | 2,000 | $67.88 | $135,768.40 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $67.41 to $68.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC |
Walker Karin LChief Accounting Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC |
Garren HidekiChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,331 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · derivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,000 Underlying: Ordinary Shares · 7,331 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC |
Garren HidekiChief Medical Officer
|
SaleOrdinary Shares, par value $0.01 per share | 7,331 | $74.00 | $542,494.00 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 19:31 UTC |
Garren HidekiChief Medical Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,331 | $24.90 | $182,541.90 |
DisclosureSEC source: 0001140361-23-030333 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,669 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · derivative · entry 6 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,331 Underlying: Ordinary Shares · 4,669 shares Expires 2031-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
SaleOrdinary Shares, par value $0.01 per share | 655 | $75.49 | $49,443.20 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 5 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F5 · price: The transaction was executed in multiple trades in prices ranging from $75.26 to $76.20, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
SaleOrdinary Shares, par value $0.01 per share | 2,534 | $74.59 | $189,009.79 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 4 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 655 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $74.16 to $75.13, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
SaleOrdinary Shares, par value $0.01 per share | 971 | $73.31 | $71,183.82 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 3 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,189 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $73.03 to $73.995, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
SaleOrdinary Shares, par value $0.01 per share | 509 | $72.45 | $36,879.04 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 2 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,160 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $71.96 to $72.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 21:15 UTC |
Garren HidekiChief Medical Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,669 | $24.90 | $116,258.10 |
DisclosureSEC source: 0001140361-23-029929 · form4.xml · nonDerivative · entry 1 Garren Hideki · CIK 0001854126 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,333 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · derivative · entry 6 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,667 Underlying: Ordinary Shares · 5,333 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on March 2, 2021, and will vest with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,362 | $75.56 | $102,910.27 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · nonDerivative · entry 5 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2023. F5 · price: The transaction was executed in multiple trades in prices ranging from $75.26 to $76.24, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
SaleOrdinary Shares, par value $0.01 per share | 959 | $74.69 | $71,624.16 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · nonDerivative · entry 4 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,362 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $74.145 to $75.13, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,914 | $73.35 | $140,399.94 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · nonDerivative · entry 3 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,321 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $73.02 to $73.905, inclusive. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
SaleOrdinary Shares, par value $0.01 per share | 1,098 | $72.52 | $79,627.51 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · nonDerivative · entry 2 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,235 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $71.96 to $72.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 01:15 UTC |
Smith Brandon S.Chief Operating Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,333 | $11.12 | $59,302.96 |
DisclosureSEC source: 0001140361-23-029930 · form4.xml · nonDerivative · entry 1 Smith Brandon S. · CIK 0001805226 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · derivative · entry 8 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,000 Underlying: Ordinary Shares · 4,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · derivative · entry 7 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares subject to the option have fully vested. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 294 | $73.14 | $21,503.16 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 6 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 3,759 | $71.96 | $270,479.22 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 5 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $71.57 to $72.41, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 12,004 | $70.99 | $852,180.77 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 4 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,053 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $70.545 to $71.4925, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
SaleOrdinary Shares, par value $0.01 per share | 2,943 | $70.02 | $206,060.91 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 3 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,057 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $69.54 to $70.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 4,000 | $12.15 | $48,600.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 2 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:49 UTC |
Zago Wagner M.Chief Scientific Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,000 | $29.81 | $447,150.00 |
DisclosureSEC source: 0001140361-23-028870 · form4.xml · nonDerivative · entry 1 Zago Wagner M. · CIK 0001708681 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · derivative · entry 8 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 15,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · derivative · entry 7 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Ordinary Shares · 5,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 25, 2021, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 361 | $72.93 | $26,327.73 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · nonDerivative · entry 6 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F5 · price: The transaction was executed in multiple trades in prices ranging from $72.545 to $73.14, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 3,811 | $71.97 | $274,270.81 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · nonDerivative · entry 5 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $71.53 to $72.41, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 12,782 | $71.00 | $907,495.16 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · nonDerivative · entry 4 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,172 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $70.53 to $71.51, inclusive. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
SaleOrdinary Shares, par value $0.01 per share | 3,046 | $69.90 | $212,915.70 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · nonDerivative · entry 3 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,954 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $69.53 to $70.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:49 UTC |
Karp Carol D.Chief Regulatory Officer
|
Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,000 | $13.53 | $202,950.00 |
DisclosureSEC source: 0001140361-23-028869 · form4.xml · nonDerivative · entry 2 Karp Carol D. · CIK 0001692214 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.